TABLE 3

Univariate and multivariate Fine-Gray competing risk models for time to defervescenceb

FactorUnivariate modelMultivariate model
SHR95% CIP valueSHR95% CIP value
Cefepime treatment0.560.40–0.77<0.010.560.40–0.77<0.01
Piperacillin-tazobactam treatment0.370.22–0.64<0.010.370.22–0.64<0.01
Carbapenem treatment (reference)
Age1.000.99–1.010.51
Neutropeniaa 1.981.02–3.820.04
Pitt bacteremia score1.141.04–1.24<0.012.211.56–3.13<0.01
Leukemia1.060.67–1.660.81
History of HCT1.180.87–1.610.27
Female gender1.240.93–1.670.14
Active chemotherapy0.750.58–0.960.02
ICU residence1.220.86–1.730.27
Intra-abdominal source0.890.64–1.240.49
Combination aminoglycoside0.970.70–1.330.84
  • a Absolute neutrophil count (ANC) < 500 cells/mm3.

  • b SHR, subhazard ratio; CI, confidence interval HCT, hematopoietic stem cell transplant; ICU, intensive care unit.